Jeffrey P Aaronson

US Patent:

20130041133, Feb 14, 2013

Filed:

Apr 4, 2011

Appl. No.:

13/639952

Inventors:

Jeffrey G. Aaronson - Philadelphia PA, US
Stanley F. Barnett - North Wales PA, US
René Bartz - Lawrenceville NJ, US
Steven L. Colletti - Princeton Junction NJ, US
Vasant R. Jadhav - Harleysville PA, US
Aaron A. Momose - Blue Bell PA, US
Anthony W. Shaw - Harleysville PA, US
David M. Tellers - Lansdale PA, US
Thomas J. Tucker - North Wales PA, US
Weimin Wang - Churchville PA, US
Yu Yuan - Orlando FL, US

International Classification:

C07K 17/00

US Classification:

530324, 530326, 530327, 530325, 530328

Abstract:

In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at any 3′ and/or 5′ end; 3) one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.

US Patent:

20220289785, Sep 15, 2022

Filed:

Jul 28, 2021

Appl. No.:

17/387495

Inventors:

- Cambridge MA, US
Steven L. COLLETTI - West Point PA, US
Vadim DUDKIN - West Point PA, US
Jeffrey AARONSON - West Point PA, US
Aaron MOMOSE - West Point PA, US
Thomas Joseph TUCKER - West Point PA, US
Yu YUAN - Orlando FL, US
Kathleen B. CALATI - Rahway NJ, US
Lu TIAN - Jamison PA, US
Rubina G. PARMAR - West Point PA, US
Anthony W. SHAW - West Point PA, US
Weimin WANG - West Point PA, US
Rachel Anne STORR - West Point PA, US
Robert A. KOWTONIUK - West Point PA, US

International Classification:

C07H 15/26
A61K 31/7056
A61K 31/713
A61K 47/54
C12N 15/113

Abstract:

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

US Patent:

20190153016, May 23, 2019

Filed:

Feb 5, 2019

Appl. No.:

16/268262

Inventors:

- Cambridge MA, US
Steven L. COLLETTI - West Point PA, US
Vadim DUDKIN - West Point PA, US
Jeffrey AARONSON - West Point PA, US
Aaron MOMOSE - West Point PA, US
Thomas Joseph TUCKER - West Point PA, US
Yu YUAN - Orlando FL, US
Kathleen B. CALATI - Rahway NJ, US
Lu TIAN - Jamison PA, US
Rubina G. PARMAR - West Point PA, US
Anthony W. SHAW - West Point PA, US
Weimin WANG - West Point PA, US
Rachel Anne STORR - West Point PA, US
Robert A. KOWTONIUK - West Point PA, US

International Classification:

C07H 15/26
C12N 15/113
A61K 31/713
A61K 47/54
A61K 31/7056

Abstract:

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

US Patent:

20190015442, Jan 17, 2019

Filed:

May 8, 2018

Appl. No.:

15/974135

Inventors:

- Rahway NJ, US
Thomas J. Tucker - North Wales PA, US
David M. Tellers - Lansdale PA, US
Boyoung Kim - Natick MA, US
Rob Burke - Encinitas CA, US
Kathleen B. Calati - Saline MI, US
Matthew G. Stanton - Needham MA, US
Rubina G. Parmar - Acton MA, US
Jeffrey G. Aaronson - San Francisco CA, US
Weimin Wang - Churchville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/7125
C12N 15/113
C12N 15/87
A61K 38/16
A61K 38/10
A61K 31/713
C12N 15/11

Abstract:

Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)-(G); wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)-(L)-(G); wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.

US Patent:

20180079769, Mar 22, 2018

Filed:

Nov 8, 2017

Appl. No.:

15/807143

Inventors:

- Cambridge MA, US
Steven L. COLLETTI - West Point PA, US
Vadim DUDKIN - West Point PA, US
Jeffrey AARONSON - West Point PA, US
Aaron MOMOSE - West Point PA, US
Thomas Joseph TUCKER - West Point PA, US
Yu YUAN - Orlando FL, US
Kathleen B. CALATI - Rahway NJ, US
Lu TIAN - Jamison PA, US
Rubina G. PARMAR - West Point PA, US
Anthony W. SHAW - West Point PA, US
Weimin WANG - West Point PA, US
Rachel Anne STORR - West Point PA, US
Robert A. KOWTONIUK - West Point PA, US

International Classification:

C07H 15/26

Abstract:

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table , which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

US Patent:

20170306324, Oct 26, 2017

Filed:

Apr 7, 2017

Appl. No.:

15/481942

Inventors:

- Cambridge MA, US
Steven L. COLLETTI - West Point PA, US
Vadim DUDKIN - West Point PA, US
Jeffrey AARONSON - West Point PA, US
Aaron MOMOSE - West Point PA, US
Thomas Joseph TUCKER - West Point PA, US
Yu YUAN - Orlando FL, US
Kathleen B. CALATI - Rahway NJ, US
Lu TIAN - Jamison PA, US
Rubina G. PARMAR - West Point PA, US
Anthony W. SHAW - West Point PA, US
Weimin WANG - West Point PA, US
Rachel Anne STORR - West Point PA, US
Robert A. KOWTONIUK - West Point PA, US

International Classification:

C12N 15/113
A61K 31/7056
C07H 15/26
A61K 31/713

Abstract:

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

US Patent:

20170189441, Jul 6, 2017

Filed:

Nov 3, 2014

Appl. No.:

15/033715

Inventors:

Steven L. COLLETTI - Kenilworth NJ, US
Thomas J. TUCKER - West Point PA, US
David M. TELLERS - West Point PA, US
Boyoung KIM - Lansdale PA, US
Rob BURKE - Philadelphia PA, US
Kathleen B. CALATI - Rahway NJ, US
Matthew G. STANTON - Marlton NJ, US
Rubina G. PARMAR - Harleysville PA, US
Jeffrey G. AARONSON - Philadelphia PA, US
Weimin WANG - Churchville PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/7125
A61K 38/10
A61K 38/16
A61K 31/713

Abstract:

Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)-(G); wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)-(L)-(G); wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.

US Patent:

20150246133, Sep 3, 2015

Filed:

May 1, 2013

Appl. No.:

14/398369

Inventors:

- Cambridge MA, US
Steven L. Colletti - West Point PA, US
Vadim Dudkin - West Point PA, US
Jeffrey Aaronson - West Point PA, US
Aaron Momose - West Point PA, US
Thomas Joseph Tucker - West Point PA, US
Yu Yuan - Orlando FL, US
Kathleen B. Calati - Rahway NJ, US
Lu Tian - Jamison PA, US
Rubina G. Parmar - West Point PA, US
Anthony W. Shaw - West Point PA, US
Weimin Wang - West Point PA, US
Rachel Anne Storr - West Point PA, US
Robert A. Kowtoniuk - West Point PA, US

International Classification:

A61K 47/48
C12N 15/113
A61K 31/713

Abstract:

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.